Cargando…

Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials

BACKGROUND: Many clinical trials have assessed the effect and safety of monoclonal antibodies (MAbs) in combination with proteasome inhibitors or immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma (MM). The treatment outcomes of comparing different MAbs in combinati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Wu, Wu, Xia, Liu, Xiaoyan, Zheng, Xue, Deng, Jili, Gong, Yuping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419924/ https://www.ncbi.nlm.nih.gov/pubmed/34488679 http://dx.doi.org/10.1186/s12885-021-08588-9

Ejemplares similares

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

SLAMF8 expression predicts the efficacy of anti‐PD1 immunotherapy in gastrointestinal cancers
por: Zhang, Qun, et al.
Publicado: (2021)

Negative Regulation of Humoral Immunity Due to Interplay between the SLAMF1, SLAMF5, and SLAMF6 Receptors
por: Wang, Ninghai, et al.
Publicado: (2015)

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
por: Mu, Song, et al.
Publicado: (2015)

Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials
por: Zheng, Yanhua, et al.
Publicado: (2018)

CRISPR-Mediated Triple Knockout of SLAMF1, SLAMF5 and SLAMF6 Supports Positive Signaling Roles in NKT Cell Development
por: Huang, Bonnie, et al.
Publicado: (2016)

LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials
por: Zhao, Bai-Wei, et al.
Publicado: (2022)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Indirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies
por: Jiang, Yawen, et al.
Publicado: (2022)

Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma
por: Yokoyama, Shintaro, et al.
Publicado: (2020)

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion
por: Alvarez, Maite, et al.
Publicado: (2020)

Fibronectin glomerulopathy with monoclonal gammopathy responding to bortezomib plus dexamethasone: a case report
por: Li, Xiaoli, et al.
Publicado: (2022)

Migration of Myeloid Cells during Inflammation Is Differentially Regulated by the Cell Surface Receptors Slamf1 and Slamf8
por: Wang, Guoxing, et al.
Publicado: (2015)

Dexamethasone/prednisone: Acute pancreatitis: case report
Publicado: (2021)

PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer
por: Manson, Quirine F., et al.
Publicado: (2018)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
por: Sato, Ryo, et al.
Publicado: (2019)

Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function
por: Choi, Jin Wook, et al.
Publicado: (2020)

The Possible Role of PD-1 Protein in Ganoderma lucidum–Mediated Immunomodulation and Cancer Treatment
por: Wang, Gan, et al.
Publicado: (2019)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation
por: Wang, Mingzhu, et al.
Publicado: (2019)

Granulomatous myositis induced by anti–PD-1 monoclonal antibodies
por: Uchio, Naohiro, et al.
Publicado: (2018)

A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors
por: Barham, Whitney, et al.
Publicado: (2023)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
por: Verkleij, Christie P. M., et al.
Publicado: (2020)

Novel Role for PD-1:PD-L1 as Mediator of Pulmonary Vascular Endothelial Cell Functions in Pathogenesis of Indirect ARDS in Mice
por: Lomas-Neira, Joanne, et al.
Publicado: (2018)

CRISPR-Mediated Slamf1(Δ/Δ) Slamf5(Δ/Δ) Slamf6(Δ/Δ) Triple Gene Disruption Reveals NKT Cell Defects but Not T Follicular Helper Cell Defects
por: Hu, Joyce K., et al.
Publicado: (2016)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Two-Round Mixed Lymphocyte Reaction for Evaluation of the Functional Activities of Anti-PD-1 and Immunomodulators
por: Kwon, Minsuk, et al.
Publicado: (2018)

Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics
por: Kotraiah, Vinayaka, et al.
Publicado: (2020)

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
por: Tan, Shuguang, et al.
Publicado: (2016)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression
por: Costa, Federica, et al.
Publicado: (2021)

Immunorthodontics: PD-L1, a Novel Immunomodulator in Cementoblasts, Is Regulated by HIF-1α under Hypoxia
por: Yong, Jiawen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_agsd3vv2ch74oa03ee0d2qucki